Gene mutations and their relationship with clinical features in 100 patients with myelodysplastic syndrome

doi:10.16150/j.1671-2870.2024.03.008

Abstract

Abstract:

Objective To investigate the correlation between gene mutations and clinical features, prognosis, and the risk of acute myeloid leukemia (AML) transformation in patients with myelodysplastic syndrome (MDS). Methods We retrospectively analyzed clinical data from 100 MDS patients and next-generation sequencing（NGS） was employed to identify 34 MDS-associated gene mutations across all patients. The mutation rates and distributions were analyzed to assess the correlation of high-frequency mutations (≥10%) with clinical features, prognosis, and the risk of AML progression. Results NGS identified 32 types of gene mutations across the cohort, with 84% of patients harboring at least one mutation. Mutations were most frequently observed in the MDS-MLD subtypes (39.3%) and predominantly in patients aged ≥60 years（82.8%，53/64）. The ASXL1 gene exhibited the highest mutation ratio (26%), with TET2, U2AF1, DNMT3A, RUNX1, TP53, and SF3B1 also showing incidence higher than 10%. ASXL1 frequently co-mutated with RUNX1 and with TP53 exclusion. It revealed that higher percentages of bone marrow blasts were seen in ASXL1-positive patients, lower platelet counts in U2AF1-positive patients, and a greater prevalence of DNMT3A mutations in elderly patients (85.7%). RUNX1 mutations were associated with elevated white blood cell counts, while TP53 mutations correlated with higher IPSS-R scores（6 vs 4.5）(P=0.016 )and elevated LDH levels（P=0.002）（420 U/L vs 222 U/L）, respectively. The median follow-up period was 18.6 months, and the median overall survival was 27.1 months, with TP53 mutations being an independent predictor for poor overall survival (OS). During follow-up, 15% of patients progressed to AML, with DNMT3A mutations identified as an independent risk factor for AML transformation（HR=3.73）. Conclusions Genetic mutations are prevalent in MDS and correlate with distinct clinical features. In this cohort of MDS patients, the mutation rate of MDS-related genes is 84%. TP53 mutations were associated with poor prognosis, whereas DNMT3A mutations are linked to an increased risk of AML transformation.

Key words: Myelodysplastic syndromes, Gene mutation, Next-generation sequencing, Prognosis, Acute myeloid leukemia transformation

CLC Number:

ZHU Weiwei, LI Qian, WU Fan, ZHAI Zhimin. Gene mutations and their relationship with clinical features in 100 patients with myelodysplastic syndrome[J]. Journal of Diagnostics Concepts & Practice, 2024, 23(03): 305-312.

Figures/Tables 6

Figure 1

Figure 2

Table 1

Table 2

Figure 3

Table 3

References 24

[1]	JIANG M, CHEN M, LIU Q, et al. SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process[J]. Front Oncol, 2023, 13:1116438.
[2]	中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会, 中华医学会病理学分会. 二代测序技术在血液肿瘤中的应用中国专家共识(2018年版)[J]. 中华血液学杂志, 2018, 39(11):881-886.
	Hematologic Oncology Committee of Chinese Anti-Cancer Association, Hematology Branch of Chinese Medical Association, Pathology Branch of Chinese Medical Association. Expert consensus on the application of next-generation sequencing in hematological neoplasms (2018)[J]. Chin J Hematol, 2018, 39(11):881-886.
[3]	SCHMALBROCK L K, DOLNIK A, COCCIARDI S, et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin[J]. Blood, 2021, 137(22):3093-3104. doi: 10.1182/blood.2020007626 pmid: 33598693
[4]	FANG K, QI J, ZHOU M, et al. Clinical characteristics, prognosis, and treatment strategies of TP53 mutations in myelodysplastic syndromes[J]. Clin Lymphoma Myeloma Leuk, 2022, 22(4):224-235.
[5]	PARK H S, IM K, SHIN D Y, et al. Telomere integrated scoring system of myelodysplastic syndrome[J]. J Clin Lab Anal, 2023, 37(3):e24839.
[6]	STEENSMA D P. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?[J]. Best Pract Res Clin Haematol, 2021, 34(4):101327.
[7]	LI W. Leukemia[M]// LIW. The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. Brisbane (AU): Exon Publications, 2022.
[8]	HAFERLACH T, NAGATA Y, GROSSMANN V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes[J]. Leukemia, 2014, 28(2):241-247. doi: 10.1038/leu.2013.336 pmid: 24220272
[9]	李冰, 王静雅, 刘晋琴, 等. 靶向测序检测511例骨髓增生异常综合征患者基因突变[J]. 中华血液学杂志, 2017, 38(12):1012-1016.
	LI B, WANG J Y, LIU J Q, et al. Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing[J]. Chin J Hematol, 2017, 38(12):1012-1016.
[10]	YANG X, ZHAO H, WU H, et al. Analysis of gene mutation characteristics and its correlation with prognosis in patients with myelodysplastic syndromes[J]. Clin Chim Acta, 2024, 554:117789.
[11]	WU K, NIE B, LI L, et al. Bioinformatics analysis of high frequency mutations in myelodysplastic syndrome-related patients[J]. Ann Transl Med, 2021, 9(19):1491. doi: 10.21037/atm-21-4094 pmid: 34805353
[12]	NAZHA A, KOMROKJI R, MEGGENDORFER M, et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes[J]. J Clin Oncol, 2021, 39(33):3737-3746.
[13]	黄龄乐, 颜新宇, 刘兰香, 等. 骨髓增生异常综合征：190例患者的遗传学危险因素及预后分析[J]. 肿瘤, 2023, 43(2):83-95.
	HUANG L L, YAN XY, LIU LX, et al. Myelodysplastic syndrome: an analysis of the genetic risk factors and prognosis of 190 patients[J]. Tumor, 2023, 43(2):83-95.
[14]	WANG C, SALLMAN D A. What are the prospects for treating TP53 mutated myelodysplastic syndromes and acute myeloid leukemia[J]. Cancer J, 2022, 28(1):51-61.
[15]	BERNARD E, NANNYA Y, HASSERJIAN R P, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes[J]. Nat Med, 2020, 26(10):1549-1556.
[16]	ABAZA Y, ZEIDAN A M. Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes[J]. Cells, 2022, 11(14):2249.
[17]	CHOUDHARY G S, PELLAGATTI A, AGIANIAN B, et al. Activation of targetable inflammatory immune signa-ling is seen in myelodysplastic syndromes with SF3B1 mutations[J]. Elife, 2022, 11:e78136.
[18]	RUJIRACHAIVEJ P, SIRIBOONPIPUTTANA T, RERKAMNUAYCHOKE B, et al. The frequency of SF3B1 mutations in thai patients with myelodysplastic syndrome[J]. Asian Pac J Cancer Prev, 2018, 19(7):1825-1831.
[19]	HUGHES C F M, GALLIPOLI P, AGARWAL R. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome[J]. Pathology, 2021, 53(3):328-338.
[20]	MADAN V, LI J, ZHOU S, et al. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes[J]. Am J Hematol, 2020, 95(2):133-143. doi: 10.1002/ajh.25673 pmid: 31680297
[21]	LIANG S, ZHOU X, PAN H, et al. Prognostic value of DNMT3A mutations in myelodysplastic syndromes: a meta-analysis[J]. Hematology, 2019, 24(1):613-622.
[22]	JUNG H A, JUNG C W, JANG J H. Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome[J]. Korean J Intern Med, 2021, 36(2):413-423. doi: 10.3904/kjim.2019.385 pmid: 33086776
[23]	GOEL H, RAHUL E, GUPTA I, et al. Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia[J]. Am J Blood Res, 2021, 11(5):472-497.
[24]	韩丹丹, 完晓菊, 陈洋, 等. 1例脐血移植植入失败伴免疫性血小板输注无效MDS患者报告[J]. 安徽医学, 2023, 44(8):900-902.
	HAN D D, WAN X J, CHEN Y, et al. 1 Case of failed hematopoietic stem cell transplantation with refractory immune thrombocytopenia in a patient with MDS[J]. Anhui Med, 2023, 44(8):900-902.

Indice	NGS-positive group (n=84)	NGS-negative group (n=16)	Z/χ²	P
Male/Female	54/30	12/4	0.688	0.407
Age（years）	66 (17-91)	65(39-78)	-0.522	0.601
White blood cell count（×10⁹/L）	2.52 (0.65-57.34)	3.26 (0.43-7.84)	-0.823	0.411
Neutrophil count, NC（×10⁹/L）	1.21 (0.12-43.92)	1.23 (0.06-6.20)	-0.606	0.544
Hemoglobin (g/L)	64.0 (25-133)	77.0 (30-109)	-0.809	0.419
Platelet (×10⁹/L）	53.5 (3-1086)	47.5 (5-163)	-0.663	0.507
Bone marrow blasts (%)	4.0 (0-18)	2.0 (0-18)	-0.907	0.364
Bone marrow blasts≥5% (n/%)	35 (41.7)	5 (31.3)	0.608	0.436
High-risk karyotype(n/%)	16 (19.0)	2 (12.5)	0.073	0.532
LDH	237.5 (76-1453)	192.0 (89-609)	-1.608	0.108
LDH>250 U/L (n/%)	38 (45.2)	5 (31.3)	1.073	0.3
IPSS-R Score	5.0 (1.5-9.5)	3.5 (2.0-8.0)	-1.072	0.284
IPSS-R Score>3.5 (n/%)	55 (65.5)	8 (50.0)	1.381	0.24
Demethylation therapy (n/%)	65 (77.4)	9 (56.3)	2.118	0.146

		Univariate HR (95%CI, P)	Multivariate HR (95%CI, P)
Age (years）	≥60	8.33 (17.49-31.11, 0.004)	4.01 (1.90-8.44, <0.001)
	<60
Hemoglobin (g/L)	≥60	3.88 (10.56-36.44, 0.049)
	<60
Platelet (×10⁹/L）	≥80	6.30 (16.92-31.68, 0.012)
	<80		2.13 (1.06-4.25, 0.033)
IPSS-R Score	>3.5	13.61 (11.19-26.41, 0.001)	2.69 (1.25-5.78, 0.011)
	≤3.5
TP53	Mutation	6.43 (6.64-10.97, 0.011)	2.52 (1.20-5.29, 0.014)
	Non-mutation
Transformed to AML	Yes	12.69 (7.55-23.45, 0.001)	2.64 (1.31-5.34, 0.007)
	No

Item	Univariate HR(P)	Multivariate HR (95%CI, P)
Bone marrow blasts (%)
≥5
<5	5.149 (0.023)
IPSS-R Score
>3.5		12.20 (1.59-93.67, 0.016)
≤3.5	8.537 (0.003)
DNMT3A
Mutation		3.73 (1.14-12.19, 0.029)
Non-mutation	4.078 (0.043)